Chitosan as a Nasal Delivery System: The Effect of Chitosan Solutions on in Vitro and in Vivo Mucociliary Transport Rates in Human Turbinates and Volunteers

Aspden, Trudi; Mason, J. D. T.; Jones, Nicholas S.; Lowe, James; Skaugrud, Øyvind; Illum, Lisbeth

doi:10.1021/js960182o

Cited by 238 publications

(111 citation statements)

References 28 publications

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…18 It has been proven that chitosan is non-toxic in both experimental animals 19 and humans. 20 Chitosan nanoparticles have the potential to act as mediators of protein antigens or plasmid DNA, and to protect against biological degradation by nucleases. 21,22 Recently, chitosan nanoparticles have also been utilized for sustained release of various drugs, including oligonucleotides.…”

Section: Introductionmentioning

confidence: 99%

Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles

Zhao¹,

Zhang²,

Zhang³

et al. 2014

IJN

View full text Add to dashboard Cite

Optimal preparation conditions of Newcastle disease virus (NDV) F gene deoxyribonucleic acid (DNA) vaccine encapsulated in chitosan nanoparticles (pFNDV-CS-NPs) were determined. The pFNDV-CS-NPs were prepared according to a complex coacervation method. The pFNDV-CS-NPs were produced with good morphology, high stability, a mean diameter of 199.5 nm, encapsulation efficiency of 98.37%±0.87%, loading capacity of 36.12%±0.19%, and a zeta potential of +12.11 mV. The in vitro release assay showed that the plasmid DNA was sustainably released from the pFNDV-CS-NPs, up to 82.9%±2.9% of the total amount. Cell transfection test indicated that the vaccine expressed the F gene in cells and maintained good bioactivity. Additionally, the safety of mucosal immunity delivery system of the pFNDV-CS-NPs was also tested in vitro by cell cytotoxicity and in vivo by safety test in chickens. In vivo immunization showed that better immune responses of specific pathogen-free chickens immunized with the pFNDV-CS-NPs were induced, and prolonged release of the plasmid DNA was achieved compared to the chickens immunized with the control plasmid. This study lays the foundation for the further development of mucosal vaccines and drugs encapsulated in chitosan nanoparticles.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles

Zhao¹,

Zhang²,

Zhang³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…Chitosan is also a polyelectrolyte with a positively charged backbone and is readily soluble in slightly acidic conditions (12). Chitosan was proven to be biodegradable, biocompatible, bioadhesive, and nontoxic in a range of toxicity tests (13). Because of these desirable properties, it has been extensively used in a variety of food, cosmetic, and pharmaceutical fields.…”

mentioning

confidence: 99%

“…Because of these desirable properties, it has been extensively used in a variety of food, cosmetic, and pharmaceutical fields. Specifically, chitosan has been extensively used in drug delivery (13), including pulmonary drug delivery (12).…”

mentioning

confidence: 99%

Chitosan Enhances the In Vitro Surface Activity of Dilute Lung Surfactant Preparations and Resists Albumin-Induced Inactivation

et al. 2006

View full text Add to dashboard Cite

ABSTRACT:Chitosan is a natural, cationic polysaccharide derived from fully or partially deacetylated chitin. Chitosan is capable of inducing large phospholipid aggregates, closely resembling the function of nonionic polymers tested previously as additives to therapeutic lung surfactants. The effects of chitosan on improving the surface activity of a dilute lung surfactant preparation, bovine lipid extract surfactant (BLES), and on resisting albumin-induced inactivation were studied using a constrained sessile drop (CSD) method. Also studied in parallel were the effects of polyethylene glycol (PEG, 10 kD) and hyaluronan (HA, 1240 kD). Both adsorption and dynamic cycling studies showed that chitosan is able to significantly enhance the surface activity of 0.5 mg/mL BLES and to resist albumin-induced inactivation at an extremely low concentration of 0.05 mg/mL, 1000 times smaller than the usual concentration of PEG and 20 times smaller than HA. Optical microscopy found that chitosan induced large surfactant aggregates even in the presence of albumin. Cytotoxicity tests confirmed that chitosan has no deleterious effect on the viability of lung epithelial cells. The experimental results suggest that chitosan may be a more effective polymeric additive to lung surfactant than the other polymers tested so far. (1) suggested the use of low-cost, water-soluble nonionic polymers, such as dextran, PEG, and polyvinylpyrrolidone (PVP), as additives to therapeutic lung surfactants. Both in vitro (1-6) and in vivo (7-9) trials have shown that these nonionic polymers can significantly improve the surface activity of different therapeutic lung surfactants and effectively reverse inactivation due to a variety of inhibitory substances.More recently, Lu et al. (10,11) reported the use of an anionic polymer, HA, as a surfactant additive. Both in vitro (10) and in vivo (11) tests showed that the addition of HA at different molecular weights to various therapeutic lung surfactants can effectively reverse serum-and meconium-induced inactivation. These studies, therefore, tentatively proved the feasibility of using an ionic polymer as a lung surfactant additive. Following these studies, we investigate here the use of a cationic polymer, chitosan, as a potential lung surfactant additive.Chitosan is a natural polysaccharide composed of linear ␤-(1¡4)-linked 2-amino-2-deoxy-␤-D-glucan combined with glycosidic linkages (12). It is derived from fully or partially deacetylated chitin, which is extracted from crustacean shells. Chitosan is also a polyelectrolyte with a positively charged backbone and is readily soluble in slightly acidic conditions (12). Chitosan was proven to be biodegradable, biocompatible, bioadhesive, and nontoxic in a range of toxicity tests (13). Because of these desirable properties, it has been extensively used in a variety of food, cosmetic, and pharmaceutical fields. Specifically, chitosan has been extensively used in drug delivery (13), including pulmonary drug delivery (12).Chan and co-workers (14 -17) have recently...

show abstract

“…It is a potentially useful pharmaceutical material owing to its good biocompatibility and low toxicity. [1][2][3][4][5] For these reasons, it has been used as a material for carriers in delivery systems for biologically active substances. Previously chitosan microparticles were prepared using a cross-linking agent combined with an emulsification technique.…”

mentioning

confidence: 99%

Formation of Biocompatible Nanoparticles by Self-Assembly of Enzymatic Hydrolysates of Chitosan and Carboxymethyl Cellulose

Ichikawa

Iwamoto

Watanabe

2005

Bioscience, Biotechnology, and Biochemistry

View full text Add to dashboard Cite

Chitosan as a Nasal Delivery System: The Effect of Chitosan Solutions on in Vitro and in Vivo Mucociliary Transport Rates in Human Turbinates and Volunteers

Cited by 238 publications

References 28 publications

Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles

Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles

Chitosan Enhances the In Vitro Surface Activity of Dilute Lung Surfactant Preparations and Resists Albumin-Induced Inactivation

Formation of Biocompatible Nanoparticles by Self-Assembly of Enzymatic Hydrolysates of Chitosan and Carboxymethyl Cellulose

Contact Info

Product

Resources

About